Abstract

In order to provide a novel human-derived monoclonal antibody that binds to a spike (S) protein of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to neutralize SARS-CoV-2, an antigen-binding fragment thereof, and a pharmaceutical composition containing the antibody or the antigen-binding fragment thereof, the present invention provides: a human-derived monoclonal antibody against SARS-CoV-2, the antibody binding to the S protein of SARS-CoV-2 to neutralize viral activity of the S protein including an immune escape mutation; an antigen-binding fragment thereof; nucleic acids encoding the antibody and the antigen-binding fragment thereof; and a pharmaceutical composition for treating or preventing a SARS-CoV-2 coronavirus infectious disease, the pharmaceutical composition containing the antibody or the antigen-binding fragment thereof.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 31/14 - Antivirals for RNA viruses

Abstract

Provided are a novel anti-HSV monoclonal antibody, etc. The anti-HSV monoclonal antibody or an antigen-binding fragment thereof that specifically binds to the envelope glycoprotein of herpes simplex virus (HSV), wherein: (i) the heavy chain variable region contains (a) the amino acid sequence of heavy chain CDR1 containing the amino acid sequence of SEQ ID NO: 2, (b) the amino acid sequence of heavy chain CDR2 containing the amino acid sequence of SEQ ID NO: 3, and (c) the amino acid sequence of heavy chain CDR3 containing the amino acid sequence of SEQ ID NO: 4, and (ii) the light chain variable region contains (a) the amino acid sequence of light chain CDR1 containing the amino acid sequence of SEQ ID NO: 6, (b) the amino acid sequence of light chain CDR2 containing the amino acid sequence of SEQ ID NO: 7, and (c) the amino acid sequence of light chain CDR3 containing the amino acid sequence of SEQ ID NO: 8; or (i) the heavy chain variable region contains (d) the amino acid sequence of heavy chain CDR1 containing the amino acid sequence of SEQ ID NO: 12, (e) the amino acid sequence of heavy chain CDR2 containing the amino acid sequence of SEQ ID NO: 13, and (f) the amino acid sequence of heavy chain CDR3 containing the amino acid sequence of SEQ ID NO: 14, and (ii) the light chain variable region contains (d) the amino acid sequence of light chain CDR1 containing the amino acid sequence of SEQ ID NO: 16, (e) the amino acid sequence of light chain CDR2 containing the amino acid sequence of SEQ ID NO: 17, and (f) the amino acid sequence of light chain CDR3 containing the amino acid sequence of SEQ ID NO: 18.

IPC Classes  ?

• C12N 15/13 - Immunoglobulins
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 31/22 - Antivirals for DNA viruses for herpes viruses
• C07K 16/08 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression

Abstract

The purpose of the present invention is to provide: a novel human-derived monoclonal antibody that binds to a spike (S) protein of a severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) to neutralize the SARS-CoV-2; an antigen-binding fragment of the antibody; and a pharmaceutical composition containing the antibody or the antigen-binding fragment thereof. In order to achieve this purpose, the present invention provides: a human-derived monoclonal antibody against a SARS-CoV-2, which binds to an S protein of the SARS-CoV-2 to neutralize the viral activities, including an immune escape mutation, of the SARS-CoV-2; an antigen-binding fragment of the antibody; nucleic acids respectively encoding the antibody and the antigen-binding fragment of the antibody; and a pharmaceutical composition for treating or preventing SARS-CoV-2 infection, which contains the antibody or an antigen-binding fragment thereof.

IPC Classes  ?

• C12N 15/13 - Immunoglobulins
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 31/14 - Antivirals for RNA viruses
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
• C12P 21/08 - Monoclonal antibodies

Abstract

The present invention provides a human-derived monoclonal antibody against SARS-CoV-2 coronavirus, said antibody binding to the S protein of SARS-CoV-2 coronavirus and neutralizing the viral activity, an antigen-binding fragment thereof, a nucleic acid encoding the antibody or the antigen-binding fragment thereof, and a pharmaceutical composition for treating or preventing SARS-CoV-2 coronavirus infection, said composition containing the antibody or the antigen-binding fragment thereof.

IPC Classes  ?

• C12N 15/13 - Immunoglobulins
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 31/14 - Antivirals for RNA viruses
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12P 21/08 - Monoclonal antibodies

Abstract

The purpose of the present invention is to provide: a novel human-derived monoclonal antibody that binds to a spike (S) protein of a severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) to neutralize the SARS-CoV-2; an antigen-binding fragment of the antibody; and a pharmaceutical composition containing the antibody or an antigen-binding fragment thereof. The present invention provides: a human-derived monoclonal antibody against a SARS-CoV-2, which binds to an S protein of the SARS-CoV-2 to neutralize viral activities, including an immune escape mutation, of the SARS-CoV-2; an antigen-binding fragment of the antibody; nucleic acids respectively encoding the antibody and the antigen-binding fragment of the antibody; and a pharmaceutical composition for treating or preventing SARS-CoV-2 infection, which contains the antibody or an antigen-binding fragment thereof.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 31/14 - Antivirals for RNA viruses
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/13 - Immunoglobulins
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12P 21/08 - Monoclonal antibodies

Abstract

The present invention provides a humanized anti-HMGB1 antibody which specifically binds to a sequence consisting of the C-terminal 8 amino acid residues (EEEDDDDE) of HMGB1 protein and is effective for treatment or prevention of various inflammatory diseases related to this protein, as well as an antigen-binding fragment thereof. The present invention also provides a pharmaceutical composition comprising such an antibody or antigen-binding fragment thereof.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention provides: a humanized anti-HMGB1 antibody that binds specifically to a sequence consisting of an eight-amino-acid residue (EEEDDDDE) at the C terminal of the HMGB1 protein, and that is effective in the treatment or prophylaxis of various inflammatory diseases related to said protein; an antigen-binding fragment of said antibody; and a pharmaceutical composition including said antibody or said antigen-binding fragment thereof.

IPC Classes  ?

• C07K 16/46 - Hybrid immunoglobulins
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 25/04 - Centrally acting analgesics, e.g. opioids
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/09 - Recombinant DNA-technology

Abstract

The present invention provides: a novel human-derived monoclonal antibody that binds specifically to the F protein of the human metapneumovirus and that neutralizes the human metapneumovirus; an antigen-binding fragment of said antibody; and a pharmaceutical composition that includes said antibody or said antigen-binding fragment thereof.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61K 39/155 - Paramyxoviridae, e.g. parainfluenza virus
• A61P 31/14 - Antivirals for RNA viruses
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/09 - Recombinant DNA-technology

Abstract

The present invention provides: a novel human-derived monoclonal antibody which can bind specifically to each of toxins (toxin A and toxin B) produced from Clostridium difficile to exsert an excellent neutralizing activity, and an antigen-binding fragment of the antibody; and a pharmaceutical composition for treating infection with Clostridium difficile, which comprises the antibody or an antigen-binding fragment of the antibody.

IPC Classes  ?

• C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 1/12 - Antidiarrhoeals
• A61P 39/02 - Antidotes
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/09 - Recombinant DNA-technology
• C12P 21/08 - Monoclonal antibodies

Abstract

The present invention provides: a method for producing an antibody having a high biological activity when producing, in various animal cells, antibodies having a complement-dependent biological activity, particularly a method for producing, in an animal cell, antibodies having a high complement-dependent biological activity, said method being characterized by using a host animal cell in which a gene encoding a protein having a β-1,4-galactosyltransferase (B4Gal-T) activity is expressed; an antibody produced by the method; and a host cell line which can express the antibody in a steady manner.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12P 21/08 - Monoclonal antibodies
• C12N 15/09 - Recombinant DNA-technology

Abstract

The present invention provides a pharmaceutical composition for human cytomegalovirus HCMV causative of various disease states, the composition comprising a monoclonal antibody and an antigen-binding fragment thereof that specifically binds to the AD1 region of glycoprotein gB and that has excellent neutralizing capacity. The present invention provides: a monoclonal antibody and an antigen-binding fragment thereof having an excellent neutralizing capacity and cell-to-cell infection blocking capacity and specifically binding to a discontinuous sequence occurring in the HCMV AD1 region; a pharmaceutical composition comprising the antibody or the fragment thereof; and the like.

IPC Classes  ?

• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 39/42 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum viral

Abstract

Disclosed herein are anti-hGM-CSF monoclonal antibodies and antigen-binding fragments of such antibodies, with improved neutralizing capacity to hGM-CSF activity. Pharmaceutical compositions comprising such an antibody or antigen-binding fragment are also provided. The present invention is useful for the treatment of various diseases that are associated with aberrant expression of hGM-CSF.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
• C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
• C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Abstract

Disclosed are: a pharmaceutical composition which comprises a monoclonal antibody capable of binding specifi-cally to an AD1 region of gB glycoprotein of human cytomegalovirus (HCMV) (which is a virus causing various disease condi-tions) and having an excellent neutralizing ability for HCMV and an antigen-binding fragment of the monoclonal antibody; a monoclonal antibody which can bind specifically to a discontinuous sequence occurring in an AD1 region of HCMV and has an excellent neutralizing ability for HCMV and an inhibitory ability on the intercellular infection of HCMV, and an antigen-binding fragment of the monoclonal antibody; a pharmaceutical composition comprising the antibody or a fragment thereof; and others.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 15/06 - Antiabortive agentsLabour repressants
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 27/02 - Ophthalmic agents
• A61P 31/22 - Antivirals for DNA viruses for herpes viruses
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/09 - Recombinant DNA-technology
• C12P 21/08 - Monoclonal antibodies

Abstract

Disclosed are: a pharmaceutical composition which comprises a monoclonal antibody having an excellent affinity and an excellent neutralizing ability for human cytomegalovirus (HCMV) (which a virus causing various disease conditions) and also having an inhibitory ability on the intercellular infection of HCMV and an antigen-binding fragment of the monoclonal antibody; a monoclonal antibody which can bind specifically to a specific sequence occurring in an AD2 region of gB glycoprotein of HCMV, has an excellent affinity and an excellent neutralizing ability for HCMV, and also has an inhibitory ability on the intercellular infection of HCMV, and an antigen-binding fragment of the monoclonal antibody; a pharmaceutical composition comprising the antibody or a fragment thereof; and others.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 15/06 - Antiabortive agentsLabour repressants
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 27/02 - Ophthalmic agents
• A61P 31/22 - Antivirals for DNA viruses for herpes viruses
• C07K 16/08 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12P 21/08 - Monoclonal antibodies

Abstract

Disclosed are: a pharmaceutical composition which comprises a monoclonal antibody capable of binding specifically to an AD1 region of gB glycoprotein of human cytomegalovirus (HCMV) (which is a virus causing various disease conditions) and having an excellent neutralizing ability for HCMV and an antigen-binding fragment of the monoclonal antibody; a monoclonal antibody which can bind specifically to a discontinuous sequence occurring in an AD1 region of HCMV and has an excellent neutralizing ability for HCMV and an inhibitory ability on the intercellular infection of HCMV, and an antigen-binding fragment of the monoclonal antibody; a pharmaceutical composition comprising the antibody or a fragment thereof; and others.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 15/06 - Antiabortive agentsLabour repressants
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 27/02 - Ophthalmic agents
• A61P 31/22 - Antivirals for DNA viruses for herpes viruses
• C07K 16/08 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12P 21/08 - Monoclonal antibodies

Abstract

Disclosed are: a human monoclonal antibody having excellent affinity to and an excellent neutralization activity on an midkine (sometimes referred to as "MDK") that induces various disease states; a pharmaceutical composition containing the antibody; and others. Specifically disclosed are: a human monoclonal antibody capable of binding to a human MDK, or an antigen-binding fragment thereof; a pharmaceutical composition containing the antibody or the fragment; and others.  The pharmaceutical composition can be used for the prevention or treatment of autoimmune diseases, inflammatory diseases, cancer, endometriosis, vascular occlusive diseases and the like.

IPC Classes  ?

• C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 15/00 - Drugs for genital or sexual disordersContraceptives
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents
• A61P 37/02 - Immunomodulators
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C07K 16/46 - Hybrid immunoglobulins
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/09 - Recombinant DNA-technology
• C12P 21/08 - Monoclonal antibodies

Abstract

Disclosed herein are anti-hGM-CSF monoclonal antibodies and antigen-binding fragments of such antibodies, with improved neutralizing capacity to hGM-CSF activity. Pharmaceutical compositions comprising such an antibody or antigen-binding fragment are also provided. The present invention is useful for the treatment of various diseases that are associated with aberrant expression of hGM-CSF.

IPC Classes  ?

• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 17/06 - Antipsoriatics
• A61P 35/02 - Antineoplastic agents specific for leukemia